XenoPort to Present at the Cowen and Company 33rd Annual Health Care Conference

XenoPort to Present at the Cowen and Company 33 rd Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq: XNPT  ) announced today that it will provide access via the World Wide Web to its presentation at the Cowen and Company 33rd Annual Health Care Conference. The live presentation will occur at 7:40 a.m. Pacific Time (10:40 a.m. Eastern Time) on Wednesday, March 6, 2013. A replay of the presentation will also be available.

To access the live presentation via the Web, please go to www.XenoPort.com. Please connect to the Website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one week and will be available approximately 24 hours after the live presentation.

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. GlaxoSmithKline holds commercialization rights for Horizant in the United States during a transition period ending on April 30, 2013, following which XenoPort will be responsible for the further development, manufacturing and commercialization of Horizant. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed for the treatment of RLS in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort’s pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis. To learn more about XenoPort, please visit the Website at www.XenoPort.com.

Horizant, Regnite and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G



XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com

KEYWORDS:   United States  North America  California  Massachusetts

INDUSTRY KEYWORDS:

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2288305, ~/Articles/ArticleHandler.aspx, 10/21/2014 4:12:33 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...